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Abstract: Curcumin belongs to the family of natural compounds collectively called 
curcuminoids and it possesses remarkable beneficial anti-oxidant, anti-inflammatory,  
anti-cancer, and neuroprotective properties. Moreover it is commonly assumed that 
curcumin has also been suggested as a remedy for digestive diseases such as inflammatory 
bowel diseases (IBD), a chronic immune disorder affecting the gastrointestinal tract and 
that can be divided in two major subgroups: Crohn’s disease (CD) and Ulcerative Colitis 
(UC), depending mainly on the intestine tract affected by the inflammatory events. The 
chronic and intermittent nature of IBD imposes, where applicable, long-term treatments 
conducted in most of the cases combining different types of drugs. In more severe cases 
and where there has been no good response to the drugs, a surgery therapy is carried out. 
Currently, IBD-pharmacological treatments are generally not curative and often present 
serious side effects; for this reason, being known the relationship between nutrition and 
IBD, it is worthy of interesting the study and the development of new dietary strategy. The 
curcumin principal mechanism is the suppression of IBD inflammatory compounds (NF-κB) 
modulating immune response. This review summarizes literature data of curcumin as  
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anti-inflammatory and anti-oxidant in IBD, trying to understand the different effects in  
CD e UC. 
Keywords: curcumin; inflammatory bowel disease (IBD); inflammation; innovative treatments 
 
1. Introduction 
Curcumin, the active yellow pigment of the turmeric spice, is an herb belonging to the ginger family 
native to India and Southeast Asia. Curcumin is commonly used in Indian traditional cusine and 
medicine, especially in the treatment of biliary disorders, rheumatism and diabetic ulcers [1]. 
In more recent years, curcumin has regained interest due to its pharmacological actions and  
anti-inflammatory, anti-oxidant, anti-tumor, and anti-proliferative properties [1–6]. In addition, it is 
also known for its beneficial effects in neurological diseases by acting as a neuroprotective agent [7]. 
The principal mechanism, by which curcumin mediates these effects, is connected to the activity of 
suppression of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Furthermore, 
curcumin activity includes suppression of interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α), 
two main cytokines that play important roles in the regulation of inflammatory responses [6]. 
For these important activities, curcumin is considered as a valid potential drug treatment in 
inflammatory bowel disease (IBD). IBD are chronic progressive diseases defined as autoimmune 
diseases implicated in aberrant and persistent inflammation of the bowel; the two main forms are the 
Crohn’s disease (CD) and the ulcerative colitis (UC). Although IBD is normally manifested in 
adulthood, it could onset in childhood even before 2 years of age (early onset child disease, EOCD). 
This early onset is typically more extensive and characterized by rapid progression, leading to severe 
repercussion on disease course. 
Nowadays there are no therapeutic strategies able to significantly alter the natural history of IBD; 
instead, the nutritional therapy holds interesting possibilities for the treatment especially considered 
that conventional pharmacological treatments are discussed for the side-effects and/or adverse events 
particularly in early onset patients. In this review we summarized literature data of curcumin principal 
activity, trying to investigate its possible role in the treatment of IBD and to understand the different 
activities performed in CD and UC. 
2. Generalities on Inflammatory Bowel Disease 
IBD is a multifactorial disorder in which complex interactions among genetic, immune, and 
environmental factors are involved and represent a group of inflammatory intestinal idiopathic and 
chronic diseases [8]. The two main forms, CD and UC, overlap as intestinal disease and differ 
precisely in the clinical, pathogenic and biomolecular features. 
UC is a chronic inflammatory disorder restricted to the colon, characterized by abdominal pain, 
mucosal ulceration, hematochezia and diarrhea. Pediatric patients may present macroscopic skin 
lesions in the colon, blackwash ileitis and extensive colitis and periappendiceal inflammation [9]. 
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CD is an inflammatory disorder affecting the gastrointestinal tract in both children and adults. All 
layers of the intestine may be involved and normal healthy bowel can be found between sections of 
diseased bowel. The inflammation can affect the entire stretch starting from the mouth to the anus and 
in more complicated cases perianal and strictures fistulas may also arise. Given the variability of the 
disease localization the possibility to make a rapid and correct diagnosis is not so easy; initially the 
diagnosis could be done by performing the endoscopic analysis of biopsies from the patient’s 
gastrointestinal tract; then, a diagnostic workup for staging the disease especially when the onset is 
very early in pediatric patients is also very important [10]. From the literature it also appears that in a 
group of pediatric patients with EOCD an upper gastrointestinal and isolated colonic involvement is 
more frequent and more evident, compared to those patients in whom the disease occurs later [11]. 
The molecular pathogenesis of IBD is not completely understood, but among contributing factors 
may be included the bacterial translocation across a defective mucosal barrier and the imbalanced 
regulation of the intestinal immune response. The patients with IBD are defined considering the 
parameters of Montreal Classification: the disease onset, the location and the behavior. On the other 
hand, however, this classification had some limiting criteria for the pediatric patients classification. On 
this purpose on the classification of Paris has been added, for pediatric classification the growth 
failure, and the disease onset before 10 years of age (Table 1) [12]. 
Table 1. Pediatric modification of the Montreal classification for inflammatory bowel 
disease: the Paris classification. 
Classification Montreal Paris 
Age at 
Diagnosis 
A1 <17 year 
A2 17–40 year 
A3 above 40 year 
A1a 0–10 year 
A1b 10–17 year 
A2 17–40 year 
A3 > 40 year 
Location 
L1 terminal ileal ± limited cecal disease 
L2 colonic 
L3 ileocolonic 
L4 only upper disease 
L1 distal 1/3 ileum ± limited cecal disease 
L2 colonic 
L3 ileocolonic 
L4a upper disease proximal to ligament of Treitz 
L4b upper disease distal to ligament of Treitz 
and proximal to distal 1/3 ileum 
Behavior 
B1 non stricturing 
non penetrating 
B2 stricturing 
B3 penetrating 
P perianal disease modifier 
B1 non stricturing 
non penetrating 
B2 stricturing 
B3 penetrating 
B2B3 both penetrating and stricturing disease, 
either at the same or different times 
P perianal disease modifier 
Growth not classified G0 no evidence 
G1 growth delay 
Molecules 2014, 19 21130 
 
 
2.1. Environmental Exposure and Lifestyle 
The continuing changes in environmental factors, such as lifestyle, hygiene, medication, diet, affect 
the IBD onset differently and its course and prevalence is increasing worldwide [13]. The incidence is 
low in the Pacific region, Asia, South America Africa and Eastern Europe, while is very high in both 
Northern and Western Europe and in North America. Recent studies, however, have shown an increase 
of IBD in developing countries and among emigrant populations moving to industrialized  
societies [14,15]. The interaction between environmental exposure and life styles and IBD is 
observable, e.g., in the role of hygienic conditions suggesting that less hygienic situations play a 
protective role and cleaner life conditions are associated with increased rates of IBD, because in rich 
countries there is a lower rate of enteric pathogens, hot water and sanization resources [16,17]. The 
role of the breast-feeding leads as well to different conclusions as to whether it plays a protective role 
or increases the risk by altering the gut microbiota of breast-fed infants [18–21]. 
The exposure to antibiotics may influence the risk of IBD development affecting the mechanism 
that alters the gut microbiome, especially in children [22,23]. In a study of Canadian adults the 
relationship between the onset of IBD and the amount of antibiotics taken has been confirmed [24]. 
The lifestyle factors include the living setting and the dietary choices and both may play the role of 
risk or protective factors on IBD development. In the last decades much attention has also been paid to 
the living setting, analyzing the effects of the difference between living in an urban setting or in a rural 
setting on the onset and course of IBD [25]. Exposure to industrial agents and pollution may play an 
important role increasing the risk of early onset UC and DC [26]. A dietary intake rich in meats and 
fatty foods increases the risk of CD and a diet based on vegetables, fruits, fish and olive oil was 
inversely associated with CD. The different aliments can affect the gut permeability and the 
autoinflammatory response of the mucosa through microbiota alterations [27,28]. 
All findings evaluated indicate that the relationship between the different environmental factors and 
lifestyle that can affect CD and UC and the disease onset and course is complicated and the 
relationship between environment and genetic susceptibility is still unclear. 
2.2. Genetic Involvement in IBD 
The literature increasingly suggests that IBD develops in patients with a certain genetic 
predisposition and the localization, disease progressions and response to treatments have 
characteristics that strongly depend on the age of onset [29–32]. A difficult issue is that the functional 
relevance of most of the susceptibility genes is unclear and the total of loci identified until now do not 
account for the total hereditability of IBD. Even given the unproven assumptions that these loci are 
individually causal and collectively additive, the relative risk conferred by each locus is very small and 
their overall contribution would account for only 13.6% of CD and 7.5% of UC hereditability [33]. 
This difficult issue is a problem referred to the missing heritability. In addition to the variants found 
with the GWAS studies, other genes may be involved and they could be associated with the disease as 
monogenic pattern of hereditability and this could escape the association analysis [34,35]. There is in 
addition also the problem of the missing intelligibility, as it is very difficult to define and to make 
immunological sense of all these loci and pathways, both at the cellular and molecular level. Pediatric 
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IBD onset is increasing; about 20%–25% of IBD patients develop intestinal inflammation during 
childhood and adolescence and approximately 1% of children below one year develop the disease. 
Moreover very early onset IBD has an estimated incidence of 4.37/100,000 children and a prevalence 
of 14/100,000 children [36]. 
2.3. Immune Response and IBD 
From different studies can be inferred that an imbalance of pro- and anti-inflammatory factors plays 
an important role in the pathogenesis of IBD [37,38]. Both disorders, CD and UC, are characterized by 
immunological responses against (bacterial) antigens but the type of the inflammatory reaction appears 
to be distinct. Given that in UC there exists neither predominance of interferon gamma (IFN-γ) nor IL-4, 
while it is clear the up-regulation of IL-5, we can consider it more as a Type 2 Immunity (TH2) 
disease. On the other hand, as in CD areas of active inflammation with elevated IFN-γ, IL-12 and 
tumor necrosis factor (TNF) levels are observed, CD is considered a Type 1 Immunity (TH1) disease 
prototype [39]. 
It is commonly assumed that T helper cells comprise two subsets, each having different patterns of 
cytokine production in immune responses: the TH1 and the TH2, both implicated in the regulation of 
many immune response. The TH1 cells secrete in particular IFNγ, TNFα and TNFβ and IL-2, while the 
TH2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13 [40]. 
In their study, Pastorelli and colleagues showed an increased expression of IL-33 and IL-1 receptor 
ST2 in the serum and in the inflamed mucosa of the IBD patients. ST2 exists in two different splice 
variants leading to the synthesis of ST2L, a transmembrane receptor that confers IL-33’s biologic effects, 
and sST2, a soluble molecule that likely serves as a decoy receptor for IL-33. From their research it is 
clear that the system IL-33/ST2 is strongly activated and plays an important role in the pathogenesis of 
the IBD, also evident in patients with UC. Specifically, it was observed that during active UC, the 
accumulation of the intraepithelial and intracellular IL-33 as well as the decrease of the ST2L were 
regulated by TNF. In fact, the anti-TNF treatment of IBD patients, particularly those suffering from 
UC, modulates the levels of IL-33 and of sST2 [37]. 
A very recent study also shows that blockage of the IL-33 signal may help in the treatment of UC 
patients. Specifically this study demonstrates that IL-33 is able to induce the intestinal GATA-3 
(master regulatory gene) in the mucosa T cells, thus entrusting to IL-33 a mediating role in the 
intestinal inflammatory TH2 responses (pathological or not) [41]. 
By studying how genetic and epigenetic factors influence the age at onset and other clinical features 
of CD, it is possible to improve the understanding of the disease pathogenesis, in particular through the 
development of in vitro and ex vivo models reproducing the interaction between epithelial cells and 
microbiota. These models are fundamental to study also the development of novel therapeutic 
approaches aimed to restore a normal balance between immunity and environment. These data 
contribute to develop disease-specific cellular models based on induced pluripotent stem cells. 
Once the disease is started, complete healing is an exceptional outcome, suggesting that some 
epigenetic changes, such as DNA methylation, may stably affect the way that mucosal immunity 
respond to intestinal microbiota. Focusing on immune defects as well as excesses in the pathogenesis 
of IBD may be relevant for therapeutic approaches [42,43]. 
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3. IBD and Pharmacological Treatments 
The chronic and intermittent nature of inflammation in IBD requires long-term drug treatments in 
combination or alternation to different drugs. The first aim in treatment is to reduce symptoms and to 
induce the remission and then to maintain this remission for as long as possible. 
The severity, the presence of complications and the goal of the treatment (induction or maintenance 
of the remission) determine the choice of therapeutic line: aminosalicylates are the first line therapy for 
mild to moderate IBD; corticosteroids are preferred to use for moderate to severe disease, but are 
ineffective in the maintenance of remission [44] and then immuno-modulators which generally are not 
the elective choice due to their slow onset of action and toxicity [45]. Numerous studies have reported 
on the use of biological factors capable of manipulating the immune and inflammatory responses: 
inhibitors of T-Cell activation, anti-inflammatory cytokines (IL-10 or IL-11) and inhibitors of  
pro-inflammatory cytokines including TNF antagonists (infliximab, certolizumab pegol, etanercept, 
onercept, adalimumab, mitogen-activated protein kinases), inhibitors of PPARs, inhibitors of  
pro-inflammatory cytokine receptors (anti IL-6 receptor), inhibitors of TH1 polarization (anti-IL-2R 
antibodies, anti-IL-12, IL-18 and IFNγ) and adhesion molecule inhibitors (natalizumab) [46]. 
Although there are several potential therapeutic targets considered for the treatment of IBD, 
currently only a few biologic drugs have achieved any significant results and are approved for 
treatment, such as infliximab that has been introduced into clinical routine in the United States in 1988 
and continues to be effective. 
Adverse Effects of IBD Treatments 
The aminosalicylates are effective in controlling the inflammation, but may have adverse effects 
such as nausea, vomiting, heartburn, diarrhea and headache. The side effects of the corticosteroids are 
weight gain, acne, facial hair, hypertension, diabetes, bone mass loss and increased risk of infections. 
The use of immunosuppressant drugs (thiopurines, methotrexate, tacrolimus, thalidomide, 
cyclosporine and infliximab) is effective in the treatment of IBD (active or quiescent CD or in cases of 
steroid dependent UC), as well in pediatric patients [47,48], but these drugs are not without adverse 
effects, sometimes also serious as the case of methotrexate, which may cause dyspepsia, alopecia, 
myelosuppression, abdominal pain, headache and arthralgia [49]. Thalidomide, that acts as an inhibitor 
of TNFα synthesis, besides being a teratogen, could lead to peripheral neuropathy, dizziness and 
allergic reactions [47,50]. The use of tacrolimus has shown an elevated risk to develop adverse effects 
in UC patients, including the most common, finger tremors. The anti-TNFα molecules, including 
infliximab and adalimumab, cause reactivation of latent infections, cutaneous reactions (skin eruptions 
and macules), systemic and hematological complications, allergic events and local side effects [51,52]. 
Recently Lakatos et al., suggested that the use of biological drugs for a long time may increase the risk 
to develop malignancies such as the non-Hodgkins’s lymphoma [53]. 
It has also been seen that therapy with biological agents (anti-TNFα), as well as the use of 
immunosuppressants and/or the repeated use of corticosteroids, make patients much more susceptible 
to endemic and opportunistic infections by bacteria, fungi, parasites or pathogens viruses [54]. 
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Cyclosporine acts by inhibiting the production of IL-2 by activated T lymphocytes and it is used in 
the case of severe UC, but it is related to manifestations such as hypertension, impaired renal function 
and neurotoxicity (tremor or paresthesia), as well as minor adverse effect such as fever, headaches and 
diabetes mellitus [55]. 
As regards children and adolescents, researchers must bear in mind that the disease involves the 
physical but also the psychological level and drug treatments can affect the quality of life. Even if the 
strategies that involve the steroids use in children are preferable, one study performed in children 
suffering from Crohn’s disease has shown that a short course of polymeric diet was more effective 
then corticosteroid treatments [56]. Conventional medications used in the treatment of symptoms of 
IBD consist of anti-inflammatory and immuno-modulator drugs as summarized in Table 2 [44–54]. 
4. Curcumin: Potential and Limits 
Curcumin (diferuloymethane) is the most active component of the plant Curcuma longa, belonging 
to the family Zingiberaceae also known as turmeric, commonly employed as a natural food additive. It 
is an indigenous plant of India, but is also cultivated in other countries such as China and  
Sri Lanka [57]. Used in Indian and Chinese traditional medicine, it has been described as an  
anti-inflammatory, antioxidant, pro-apoptotic, chemopreventive, antitumor and antimicrobial 
compound, as reported in Table 3 [58–140]. 
Several studies have described the strongly link within these beneficial properties; indeed they don’t 
show different and separated effects, but they are related each other as a consequence of some specific 
characteristic. As an example, the anti-oxidant effect of curcumin and analogues was related to their 
anti-tumor and anti-inflammatory mechanism, as already described in recent studies [141–143]. 
Curcumin has been proposed to be a therapeutic molecule in various illnesses such as arthritis, 
cancer, diabetes, cardiovascular diseases, liver fibrosis, gall stone formation, neurological disease and 
inflammatory bowel disease [144,145]. The clinical development as a therapeutic drug is limited due 
to its poor aqueous solubility, poor absorption, biodistribution, rapid metabolism and fast  
elimination [146,147]. In the last years various natural and synthetic analogues of curcumin have been 
synthesized to improve bioavailability problems increasing its therapeutic potential, but their 
effectiveness is still controversial [148]. 
In spite of all this, the oral administration of the drug allows for an active level of curcumin in the 
gastrointestinal tract, making it a good candidate for the treatment of the diseases in this anatomical 
site [149–151]. 
How curcumin exerts its pleiotropic effects has been thoroughly investigated and a vast array of 
targets has been assumed to play a role in the disease pathogenesis. Some molecular targets include 
transcription factors, inflammatory cytokines, enzymes and the epigenetic modulation which modulate 
histone deacetylases, histone acetyltransferases, DNA methyltransferase I and miRNAs [80]. 
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Table 2. Characteristics of inflammatory bowel disease. 
 Localization Symptoms Cytokine Inflammation TH1/TH2 Treatments 
Crohn’s Disease 
(CD) 
Deep layers of the intestinal wall,  
the ileum,  
the first part of the colon,  
esophagus,  
stomach and duodenum 
Pain in the abdomen,  
diarrhoea,  
weight loss,  
rectal bleeding and fever 
Interferon gamma (IFN-Y),  
Interlukin 12 (IL-12),  
Tumor Necrosis Factor (TNF)
TH1 disease 
Anti-inflammation drugs, 
corticosteroids, 
immunomodulators and 
biologic treatments 
Ulcerative Colitis 
(UC) 
Inner lining of the colon (large 
interstine) and rectum 
Diarrhoea,  
abdominal cramps,  
rectal bleeding,  
frequent fever and nausea 
Interlukin 5 (IL-5),  
Interlukin 33/Interlukin 1,  
Receptor ST2 (IL-33/ST2) 
TH2 disease 
Aminosalicylates, 
corticosteroids, 
immunomodulators and 
biological treatments 
Table 3. Molecular targets of curcumin and relative effects and diseases involved. 
Targets of Curcumin Effects of Curcumin Diseases Involved 
Activation of redox-regulated transcription factor Nrf2 that induces heme 
oxygenase 1 (HO1) paraoxonase 1 (PON1) and GSH 3 [58,60–62] 
Free-radical-scavenging activity Chronic inflammatory diseases 
Inhibition of DNA-binding of STAT3 3 [63] Anti-inflammatory activity Chronic inflammatory diseases 
Reduced phosphorylation of cytosolic phospholipase A2 (cPLA2) limiting the 
arachidonic acid availability [64] 
Anti-inflammatory activity Chronic inflammatory diseases 
Reduced phosphorylation of IκB [65] Anti-inflammatory activity Chronic inflammatory diseases 
Cancer 
Inhibition of the transcription factor Nf-κB [65–72] 
Anti-inflammatory activity 
Anti-oxidant activity 
Tumor suppressive activity 
Chronic inflammatory diseases 
Cancer 
Inhibition of mRNA levels of COX2 and iNOS [73–76] 
Anti-inflammatory activity 
Tumor suppressive activity 
Chronic inflammatory diseases 
Cancer 
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Table 3. Cont. 
Targets of Curcumin Effects of Curcumin Diseases Involved 
Inhibition of matrix metalloproteinases MMP-9 and MMP-2 [72,77–79] 
Tumor suppressive activity 
(Anti-inflammatory activity) 
Cancer 
(Chronic inflammatory diseases) 
Inhibition of histone deacetylases (HDACs) and acetyltransferases (HATs) 
activity [80–88] 
Gene regulation Cancer 
Up-regulation and down-regulation of micro RNA (22, 199, 186, 203) [80,89–91] 
Pro-apoptotic activity 
Tumor suppressive activity 
Cancer 
Activation of caspase 3, 7, 8 and caspase 9 [92–94] Pro-apoptotic activity Cancer 
Increased cleavage of poly (ADP-ribose) polymerase (PARP) [67,95] Pro-apoptotic activity Cancer 
Up-regulation of several tumor suppressor genes [95–99] Tumor suppressive activity Cancer 
Up-regulation of different proapoptotic genes [100–103] 
Pro-apoptotic activity 
Tumor suppressive activity 
Cancer 
Inactivation of several oncogenes [104–112] Tumor suppressive activity Cancer 
Down-regulation of different antiapoptotic genes [113,114] 
Pro-apoptotic activity 
Tumor suppressive activity 
Cancer 
Inhibition of angiogenesis suppressing VEGF, Akt and PI3K [65,115–118] Tumor suppressive activity Cancer 
Inhibition of enzymes of phase I reactions [119–121] Tumor suppressive activity Cancer 
Activation of enzymes of phase II reactions [122–128] Tumor suppressive activity Cancer 
Down-regulation of androgen receptor (AR) [110,129–131] Tumor suppressive activity Cancer 
Repressed N-methyl-D-aspartate (NMDA) receptor-mediated Ca2+ [132–136] Protection from excitotoxicity Neurodegenerative diseases 
Reduced oxidative mitochondrial damage [137–140] Antioxidative activity Neurodegenerative diseases 
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In idiopathic inflammatory bowel diseases the persistent inflammation depends partially on the 
activation of NF-κB signaling cascade level or other molecular targets, as indicated in Table 3, and part 
of the pleiotropic effect of curcumin seems to due to inhibition of this pathway. In vivo and in vitro 
studies exhibit a different reaction to curcumin in both IBD form, CD and UC, probably depending on 
the kind of immune dysregulation involved, as shown in Figure 1 [152–155]. 
Figure 1. The curcumin activity in mucosal. 
 
Experimental Studies and Clinical Trials 
In their study Billerey-Larmonier et al., showed the effect of dietary curcumin in two mice strains 
(BALB/c and SJL/J) with chemically induced colitis. An improvement in the pathological condition of 
BALB/c mice, exhibiting a mixed TH1/TH2 response, was detected, while a lack of benefits was 
revealed in SJL/J mice characterized by TH1 response, suggesting a role of curcumin in regulating the 
immune response [152]. 
Other studies showed a weakened colonic inflammation in induced colitis mice and rats due to 
inhibition of NF-κB pathway, p38 mitogen-activated protein kinases (MAPK) activity and reduction of 
pro-inflammatory TH1 cytokine response, resulting in suppression of inducible nitric oxide synthase  
and lower neutrophil recruitment [156,157]. Furthermore, in mice with spontaneous development of 
intestinal inflammation the administration of the Indian spice showed a reduced inflammation in 
histological colonic pattern [158]. In the human colonic mucosa of IBD patients a reduced MAPK 
activity was detected, while IL-10 was increased and IL-1β reduced [154]. Although in mice 
experiments curcumin was administered intraparenterally, the oral administration in human patients 
highlighted improvements on the overall IBD situation, detecting however, a similar response to 
curcumin as adjuvant IBD therapy in patients with CD and UC [159,160]. The co-administration of 
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curcumin with conventional drugs was also shown to be safe and well-tolerated in IBD pediatric 
patients, and in fact no clinically significant side effects were reported [161]. 
Keeping in mind that CD is associated with a TH1/TH17 cell mediated response, while UC is 
associated with atypical TH2 response, clinical trials, unlike in vivo studies, suggest that curcumin 
could act on a common pathway shared by the two immune responses, probably NF-κB. 
To evaluate the curcumin efficacy in IBD disease a study on 10 IBD patients was conducted:  
five patients suffered from CD and five were affected by Ulcerative Proctitis, a mild form of UC. For 
this form of UC patients were administered for the first month of therapy 550 mg of curcumin twice 
daily and for the second month the same dose, but three times a day. After therapy a significant 
reduction of both the symptoms and the inflammatory indices was evident. To CD patients instead 360 
mg were administered three times per day for the first month and four times daily for the second and 
third month. Only four patients completed the study and in them an evident reduction of both the CD 
activity index and some indicative parameters was observed [162]. 
Another study was carried out in an adult woman (60 years) suffering from UC and enteropathic 
arthropathy. After having tried all medications including all possible combinations and after refusing 
treatments with biological agents because of possible side effects, she agreed to also take 500 mg of 
curcumin daily with 40 mg of prendnisone. After a year of treatment, improvements were evident to 
the extent that there were no marked ulcerations and biopsies showed a chronic inactive UC [163]. 
Considering the positive effects of curcumin obtained in these studies described above and others 
performed in patients suffering from IBD, curcumin could be an alternative and/or an additional 
treatment in controlling both CD and UC disease [151]. We report in Table 4 the main clinical trials, 
ongoing and concluded, evaluating the efficacy of curcumin in IBD. 
5. Curcumin and Inflammation 
The NF-κB transcription factor family plays a key role in several cellular functions (inflammation, 
apoptosis, cell survival, proliferation, angiogenesis and innate and acquired immunity) as well as in 
regulating the expression of more than 500 different genes involved in inflammatory and immune  
responses [155,164]. Many molecules are involved in the inflammatory response regulated by NF-κB 
pathway (e.g., TNF, IL-1, IL-6, IL-8, IL-10) as well as tissue destructive enzymes (e.g., matrix 
metalloproteinases and prostaglandins). TNF is the most promptly released cytokine upon injury  
and, through the interaction with its receptors, it regulates the production of pro-inflammatory and  
anti-inflammatory cytokines [165]. Therapies that target rate-limiting steps like TNF (such as 
infliximab), have markedly improved the autoimmune disease progression in IBD. Moreover NF-κB 
plays a pivotal role in the regulation of the adaptive phase and in the resolution of the inflammation 
through apoptosis mechanisms, including the pyroptosis IL-1β dependent one [166,167]. 
All these findings considered, the activity of curcumin in this context is very important, because it 
mediates its effects through modulation NF-κB and pro-inflammatory cytokines, such as IL-1β, TNF-α 
and IL-6 [168,169]. The transcriptional factors NF-κB as well as growth factor and growth factor receptors, 
protein kinases, adhesion molecules and enzymes are molecular targets for curcumin activity [170]. 
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Table 4. Clinical trials to assess the efficacy of curcumin in IBD. 
ClinicalTrials.gov Identifier 
Number of 
Patients (Age) 
Disease Doses of Curcumin Phase 
NCT01320436 
50  
(18 to 70 years) 
Ulcerative colitis (Disease activity score  
of >5 and ≤13 according to the Simple 
clinical colitis activity index (SCCAI) 
Patients allocated for this arm will receive 5ASA 
medication (as advised by their treating physician)  
+ 3 capsules (820 mg each) curcumin twice daily 
after meals. 
3 
NCT00889161 
11  
(8 to 18 years) 
Inflammatory bowel disease (mild 
disease or in clinical remission) [160] 
Initial dosage of 500 mg twice a day for 3 weeks. 
Using the forced dose titration design, dose will be 
titrated up to 1 g twice a day at week 3 for a total of 
three weeks and then titrated again to 2 g twice a 
day at week 6 for three weeks 
1 
NCT00793130 
30  
(18 to 75 years) 
Mild or moderate Ulcerative Colitis 
Dietary Supplement: Coltect 
Two tablets twice daily (BID) during the 2 months  
of the study. Each tablet contains 500 mg 
Curcumin, 250 mg Green tea and 100 μg 
Selenomethionine. 
Unknown 
NCT01647412 
40  
(10 to 17 years) 
Crohn’s Disease (Moderate to severely 
active CD, as defined by a PCDAI  
score >30 and <65) 
The experimental group will receive the exclusion 
diet and nutraceutical therapy (DNT) and daily 
subcutaneously administered recombinant human 
growth hormone (rhGH) for the first 26 weeks. 
After 26 weeks this group will continue on the 
exclusion diet nutraceutical therapy for the 
remaining 26 weeks of the study. 
2 
 
89  
(13 to 65 years) 
Ulcerative Colitis (patients in remission 
of disease) [148] 
Oral curcumin (2 g/day; 1 g morning and evening, 
after meals) 
Concluded 
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6. Curcumin Analogues and Nanoformulations 
This natural bioactive component has shown a wide range of biological properties and 
pharmacological actions, suggesting interesting clinical applications, but researchers must face the 
other side of the coin, that is all those factors contributing to the low bioavailability, the poor solubility 
(i.e., 0.4 mg/mL at pH 7.3) and absorption, and the rapid metabolic elimination by reduction and 
conjugation [171] causing limitations to the clinical applications. In order to solve this problem, there 
is a need to develop curcumin analogues and nanoformulations with higher metabolic stability than the 
original compound [172–174]. 
6.1. Curcumin Analogues 
Recently several studies, as those experimental in vivo evaluating the tumor cell viability, have 
demonstrated that compounds analogous to curcumin have the same beneficial properties of the original 
compound and, at the same concentration, even a better effect [175]. 
Curcumin analogues, such as dimethoxycurcumin or novel water-soluble curcumin derivatives have 
shown good pharmacological effects in metabolic disorders and in diabetes mellitus [176,177]. The 
major biochemical characteristics needed in analogues are stability, good pharmacokinetic properties, 
drug release in the correct site and decreased fluctuations [178]. Moreover recent studies support 
previous evidence that the biological activity of analogues of curcumin (as an example,  
2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone) was better than that of curcumin: the 
antioxidant and anti-cyclooxygenase activities of this compound are 2- and 7-times higher, and the 
anti-inflammatory activity 5-times higher than those of curcumin at a dose of 20 mg/kg, p.o. This 
compound, indeed, potently inhibits histamine release by altering some intracellular signaling events in 
mast cells and will be a good candidate for an anti-allergic and anti-inflammatory drug [179–182]. 
6.2. Nanoformulations 
Furthermore, to overcome the low aqueous solubility of curcumin as a therapeutic agent, many 
technologies have been developed and applied. In particular several studies have described the positive 
results obtained from the design and the development of nano-sized delivery systems for curcumin, 
including liposomes, polymeric nanoparticles and micelles, conjugates, peptide carriers, cyclodextrins, 
solid dispersions, lipid nanoparticles and emulsions [183,184]. 
Literature data report preliminary promising results obtained by experimental in vitro and  
in vivo studies, through the development of specific curcumin delivery systems protecting against the 
fast degradation and targeting the inflamed colon. The compound was encapsulated in polymeric  
pH-sensitive nanoparticles to obtain a selective and specific delivery to the inflamed mucosa. Nano-sized 
drug delivery systems represent an efficacious strategy against the inflammatory system in IBD 
treatment [185,186]. In particular recent studies show the effective anti-inflammatory properties 
(myeloperoxidase activity, a measure of neutrophil infiltration, and TNFα secretion), in vitro and in vivo, 
obtained by curcuma encapsulated in polymeric pH-sensitive nanoparticles for a selective and specific 
delivery of curcumin to the inflamed mucosa [186,187]. 
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The nanoformulation that seems to be the better solution as methods to deliver the curcumin in IBD 
condition is cyclodextrin-curcumin complex: the results obtained in vitro and in vivo confirmed that 
hydroxypropyl-β-cyclodextrin-curcumin complex represents a valuable innovative therapeutic 
approach for IBD treatment [187]. Although the nanoformulations have shown a good level of safety it 
is necessary to pay attention to their potential toxicity, especially with repeated administrations at high 
dosage [176]. 
7. Conclusions 
Curcumin is a natural compound that reduces the development of chronic experimental colitis and 
alleviates the inflammatory response whose precise modes of action is still unclear, and it seems likely 
that its molecular targets differ according to cell and disease system. Several studies have 
demonstrated the promising role of curcumin as a novel therapy for children and adults with IBD. 
To date a precise understanding of the effective dose, safe regimental therapy, and mechanism of 
action for the use of curcumin in the treatment of IBD is unknown, but there is abundant evidence 
proving its effects on the NF-κB pathway and p38 MAPK in the intestinal mucosa. 
The key role played by curcumin in the diet and its implications for the quality of life of IBD 
patients should be studied because preliminary data obtained in clinical trials are very encouraging. 
The pleiotropic role of curcumin in IBD pathogenesis and range severity of phenotype is very remarkable. 
We conclude that large-scale, double-blind trials need to be conducted to establish the role of 
curcumin in the treatment of IBD. The parameters crucial to be included in the study are disease onset, 
age of patients, pharmacological assumptions and diet interaction, administration with respect to the 
inflammation phase (acute or in regression). In case of nanoformulations, clinical trials are also 
required to establish not only the efficacy, but also the safety in case of repeated use. In conclusion we 
think that it is necessary to deepen if, how and how much curcumin is useful for preventing the 
recurrence of IBD by modifying the patient’s diet in remission periods and/or for decreasing the 
mucosal inflammation in the acute phase. 
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